//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts
Loading...
This marks an important first step toward understanding the psychological and neurobiological impacts of chronic GLP-1 receptor agonist treatment. We have a lot more work to do! 4/
I was excited to get into the lab today to help out with an experiment...until I realized I now need readers to make out the labels on eppendorfs and pipettes. #oldPIproblems 🔬🧪🔎
In this case, I think the difference is our treatment paradigm. We are using a chronic GLP-1 receptor agonist treatment regimen (similar to that humans experience), whereas most of what we know from the preclinical literature to-date is based on acute treatment.
Excited to share our new GLP-1 receptor agonist study! Chronic semaglutide potentiates motivation for small food rewards and associated cues, but reduces intake when food is freely available—surprising twist! #GLP-1, #behavior #neuroscience #pharmacology 1/ 🔗 www.biorxiv.org/cgi/content/...